Stockscreener 앱 받기
0.8024
0.05%
0.0004
시간 외 거래:
.81
0.0076
+0.95%
전일 마감가:
$0.802
열려 있는:
$0.83
하루 거래량:
2.53M
Relative Volume:
0.57
시가총액:
$24.24M
수익:
-
순이익/손실:
$-29.77M
주가수익비율:
-0.0525
EPS:
-15.2954
순현금흐름:
$-24.23M
1주 성능:
+27.34%
1개월 성능:
+200.52%
6개월 성능:
-55.42%
1년 성능:
-81.40%
1일 변동 폭
$0.74
$0.86
1주일 범위
$0.6101
$0.96
52주 변동 폭
$0.25
$4.39
Moleculin Biotech Inc Stock (MBRX) Company Profile
명칭
Moleculin Biotech Inc
전화
713-300-5160
주소
5300 MEMORIAL DRIVE, HOUSTON, TX
MBRX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MBRX
Moleculin Biotech Inc
|
0.8024 | 19.03M | 0 | -29.77M | -24.23M | -15.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.49 | 121.30B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.53 | 61.60B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.52 | 41.17B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
566.14 | 34.35B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.93 | 27.29B | 3.81B | -644.79M | -669.77M | -6.24 |
Moleculin Biotech Inc Stock (MBRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-09 | 재개 | H.C. Wainwright | Buy |
| 2025-02-12 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2022-07-18 | 재개 | Oppenheimer | Outperform |
Moleculin Biotech Inc 주식(MBRX)의 최신 뉴스
What drives Moleculin Biotech Inc. stock priceAccelerated earnings growth - Autocar Professional
What analysts say about Moleculin Biotech Inc. stockMassive wealth growth - jammulinksnews.com
Is Moleculin Biotech Inc. a good long term investmentTriple-digit return opportunities - Autocar Professional
Moleculin Biotech Inc. Stock Analysis and ForecastFree Stock Market Real-Time Monitoring - jammulinksnews.com
Moleculin appoints former Roche executive as strategic advisor - Investing.com Australia
Moleculin appoints former Roche executive as strategic advisor By Investing.com - Investing.com Nigeria
Moleculin Biotech Appoints Adriano Treve as Strategic Advisor - TipRanks
Moleculin Biotech, Inc. Appoints Adriano Treve as Strategic Advisor to Enhance Partnerships and Advance Clinical Trials - Quiver Quantitative
Moleculin Engages Industry Veteran Adriano Treve to Explore Accelerated Strategic Partnerships - GlobeNewswire
Former Roche Executive with 40-Year Track Record to Accelerate Moleculin's AML Drug Partnerships - Stock Titan
What makes Moleculin Biotech Inc. stock price move sharplySmart Trading With Safety Margin - Newser
Why Moleculin Biotech Inc. stock attracts strong analyst attentionTriple Digit Return Forecasts - Newser
Moleculin Biotech Surges 19.5%—What's Fueling the Rally? - AInvest
Moleculin Biotech Gains Approval for Phase 2B/3 AML Study - MSN
Moleculin Biotech enters $6.5 million at-the-market equity offering agreement By Investing.com - Investing.com South Africa
Moleculin Biotech Enters New Stock Offering Agreement - TipRanks
Moleculin Biotech enters $6.5 million at-the-market equity offering agreement - Investing.com
Moleculin Acquires $2M Private Grant for Brain Tumor Trial at MD Anderson - BioTecNika
Moleculin Expands Phase 3 MIRACLE Clinical Trial into the Country of Georgia, Enrollment Update and Future Plans - GlobeNewswire
Moleculin receives Georgian approval for pivotal AML treatment trial By Investing.com - Investing.com India
Moleculin receives Georgian approval for pivotal AML treatment trial - Investing.com Australia
Moleculin Biotech Stock Soars 13.44% on Clinical Trial Expansion - AInvest
Moleculin Biotech, Inc. Secures RAMPA Approval for Phase 2B/3 MIRACLE Trial in Georgia, Expanding Clinical Recruitment Efforts - Nasdaq
MBRX gains RAMPA nod for pivotal Phase 2B/3 AnnAraC AML trial | THTX SEC FilingForm 6-K - Stock Titan
Moleculin's Phase 3 AML Treatment Trial Gains Momentum: 7 Patients Treated, 16 New Sites Coming - Stock Titan
Favourable Signals For Moleculin Biotech: Numerous Insiders Acquired Stock - simplywall.st
Several Insiders Invested In Moleculin Biotech Flagging Positive News - Yahoo Finance
Moleculin Biotech Faces Nasdaq Delisting Warning - TipRanks
Healthcare Stocks to Watch: Catalyst Pharmaceuticals, AVITA Medical, and Moleculin Biotech. - AInvest
Moleculin Biotech Raises $5.9M in Public Offering - TipRanks
Health Care Stocks Stumble Amid Market Adjustments - Finimize
Moleculin Biotech's $5.9M Financing: A Lifeline for Annamycin or a Risky Gamble? - AInvest
Moleculin Biotech prices $5.9M public offering; shares down about 47% - MSN
Moleculin Biotech's 48% Plunge: Technical Sell-Off or Sector Sentiment Shift? - AInvest
Moleculin Biotech (NASDAQ:MBRX) Given Buy Rating at HC Wainwright - Defense World
Moleculin Biotech (MBRX) Rating Reiterated with $4.00 Price Target | MBRX Stock News - GuruFocus
Moleculin Receives Positive FDA Feedback on Pediatric Study Plan - GuruFocus
Moleculin Receives Positive FDA Feedback on Pediatric Study Plan for Annamycin in Children with R/R AML - GlobeNewswire
Moleculin Participates in Virtual Investor “What This Means” Seg - GuruFocus
Moleculin Biotech’s Annamycin Pediatric Study Approved by FDA - TipRanks
Moleculin Participates in Virtual Investor “What This Means” Segment - GlobeNewswire
Moleculin Biotech (MBRX) Advances Pediatric Cancer Treatment Study | MBRX Stock News - GuruFocus
Moleculin Receives Critical FDA Support for Children's Leukemia Treatment Development - Stock Titan
Moleculin Biotech, Inc. Advances Annamycin for Pediatric Cancer Treatment as FDA Approves Inclusion of Younger Patients in Clinical Study - Nasdaq
FDA agrees to Moleculin’s pediatric study plan for cancer drug - Investing.com
Moleculin Biotech announces ‘What This Means’ virtual investor segment - Yahoo Finance
What is HC Wainwright’s Estimate for MBRX Q2 Earnings? - Defense World
Moleculin Biotech Inc (MBRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.87%
0.17%
자본화:
|
볼륨(24시간):